Grandesc v. Bio Brasil: São Paulo Court Rescinds Chemotherapy Waste Box Patent Ruling
Grandesc Materiais Hospitalares LTDA successfully pursued a rescission action before the Court of Justice of São Paulo against Bio Brasil Biotecnologia LTDA, targeting patent BRMU1212933U2 covering a disposable waste box for chemotherapeutic drug derivatives. The court voided the prior appellate ruling and dismissed the underlying infringement action without merits adjudication, ordering Bio Brasil to pay attorney fees set at 10% of the case value (R$ 52,501.57).
São Paulo Court Voids Prior Ruling in Chemotherapy Waste Box Patent Dispute
This case — No. 2222495-83.2024.8.26.0000 — was brought before the Court of Justice of São Paulo by Grandesc Materiais Hospitalares LTDA against Bio Brasil Biotecnologia LTDA. The dispute centres on patent BRMU1212933U2, which covers an arrangement for a disposable waste box specifically oriented toward the containment of chemotherapeutic drug derivatives. The action was styled as a rescission action (ação rescisória) targeting the earlier appellate decision rendered in Appeal No. 1010011-76.2014.8.26.0068.
The Court of Justice of São Paulo granted the rescission request, finding it well founded. The operative effect was to undo the judgment previously rendered in the referenced appeal and, sitting as a Rescission Court (Juízo Rescisório), to dismiss the original infringement action without resolution of the merits on the basis of Article 485, item VI, of the Brazilian Code of Civil Procedure (CPC). Bio Brasil, as respondent, was ordered to bear costs, procedural expenses, and attorney fees set at 10% of the updated case value of R$ 52,501.57 pursuant to CPC Article 85, §2.
The procedural trajectory is notable: the rescission action references an underlying appeal filed in 2014, suggesting the patent dispute had been active for approximately a decade before this rescission concluded the matter. The dismissal without resolution of the merits under CPC Article 485(VI) — which concerns cases where a judgment was rendered by a court lacking jurisdiction or with procedural deficiency — means the substantive infringement question was never definitively adjudicated. The public record does not disclose settlement terms or whether either party intends further litigation over the patent.
Filing to Case Accepted in 0 days
Closed 23 September 2025; filing date not recorded in public docket
Rescission granted: what the São Paulo ruling means for both parties
What a rescission action (ação rescisória) does under Brazilian law
An ação rescisória is a specific procedural vehicle under Brazilian civil procedure that allows a party to annul a final judicial decision on defined grounds. Here, the court sitting as Juízo Rescisório granted the request, undoing the judgment in Appeal No. 1010011-76.2014.8.26.0068. The original action was then dismissed without merits under CPC Art. 485(VI), meaning the infringement question was never substantively resolved.
CPC Art. 485(VI) dismissalGrandesc achieves nullification of adverse appellate ruling
Grandesc’s rescission request was deemed well founded, effectively erasing the prior appellate judgment that had stood against it. By securing dismissal of the original action without merits resolution rather than an adverse finding on infringement, Grandesc avoids a precedent that could have constrained enforcement of BRMU1212933U2. The patent remains potentially enforceable, subject to any validity challenges Bio Brasil may bring in separate proceedings.
Prior judgment nullifiedBio Brasil bears costs despite no merits ruling on infringement
Bio Brasil, as respondent, was ordered to pay procedural costs, expenses, and attorney fees of 10% on the updated case value of R$ 52,501.57 — a financial penalty despite the absence of a merits finding. The dismissal without prejudice to merits also leaves Bio Brasil exposed to potential re-litigation of the underlying infringement claim if Grandesc elects to re-file, as Art. 485 dismissals do not carry res judicata effect on the substantive dispute.
Costs awarded against respondentChemotherapy waste containment IP remains unresolved and commercially live
For companies operating in oncology consumables, hospital waste management, or chemotherapy drug handling, BRMU1212933U2 survives this litigation without a merits-based validity or infringement determination. The decade-long dispute trajectory suggests the technology area carries meaningful commercial stakes. Competitors should treat the patent as enforceable until and unless a Brazilian court or the INPI rules otherwise on the substance.
Patent enforceability liveFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | GRANDESC MATERIAIS HOSPITALARES LTDA | Individual | Medical/hospital supplies distributor — holder of BRMU1212933U2 chemotherapy waste containment patentSearch in Eureka ↗ |
| Defendant | BIO BRASIL BIOTECNOLOGIA LTDA. | Individual | Brazilian biotechnology company named as respondent in rescission action over chemotherapy waste box patentSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The court’s operative language — granting the rescission request and simultaneously sitting as Juízo Rescisório to dismiss the original action under CPC Art. 485(VI) — reflects the dual-phase structure of Brazilian rescission proceedings. The iudicium rescindens annuls the prior appellate judgment, while the iudicium rescissorium replaces it with a fresh ruling, here a procedural dismissal. Critically, Art. 485(VI) dismissals carry no res judicata on the merits, leaving Grandesc free in principle to re-assert the underlying infringement claim in new proceedings.
BRMU1212933U2 — Disposable Waste Box for Chemotherapeutic Drug Derivatives
BRMU1212933U2 is a Brazilian utility model patent — designated by the ‘MU’ classification under INPI’s system — covering an arrangement for a disposable waste box oriented specifically to the containment and disposal of chemotherapeutic drug derivatives. Utility models in Brazil protect functional innovations and carry a shorter examination timeline than invention patents, with protection typically lasting ten years from filing. The patent’s focus on chemotherapy waste aligns with Brazilian regulatory requirements for the safe handling and disposal of cytotoxic materials in clinical and hospital settings.
Chemotherapy waste containment is a tightly regulated product category in Brazil, governed by ANVISA and environmental health rules that mandate specific disposal protocols for cytotoxic residues. A utility model covering the physical arrangement of a disposable waste box in this context could provide meaningful market protection against competing product designs, as the functional configuration — rather than the material alone — is the protectable element. For hospital supply manufacturers and distributors operating in Brazil’s oncology consumables market, this patent represents a potentially significant barrier to product line expansion.
Should you run an FTO against BRMU1212933U2?
Any company manufacturing, importing, or distributing disposable waste containment solutions for chemotherapy or cytotoxic drug handling in Brazil should treat BRMU1212933U2 as a live FTO concern. The litigation between Grandesc and Bio Brasil closed on procedural grounds — not on a finding of non-infringement or invalidity — meaning the patent’s enforceability was never tested. Product teams developing waste box configurations for hospital or oncology settings should map their designs against the utility model’s claims before entering the Brazilian market.
PatSnap Eureka’s FTO Search Agent can retrieve the full claims, prosecution history, and legal status of BRMU1212933U2 from the INPI register, identify design-arounds in adjacent patent families, and surface any pending validity challenges or administrative proceedings. For R&D teams working on cytotoxic waste management products, an automated FTO sweep across Brazilian utility models in this product category is a low-cost step that can prevent costly litigation exposure of the kind documented in this decade-long dispute.
Run a freedom-to-operate analysis on BRMU1212933U2 to assess your product’s exposure
Run FTO in Eureka →Similar Patent Disputes: Chemotherapy Consumables & Brazilian Utility Models
Cases involving medical consumable utility model patents and rescission actions at the Court of Justice of São Paulo — relevant to oncology supply chain IP strategy.
What this case signals for the oncology consumables IP landscape in Brazil
A decade-long dispute resolved procedurally — not on the merits — leaves the patent in force and enforcement risk open.
CPC Art. 485(VI) dismissals do not extinguish infringement claims
A dismissal without resolution of the merits under Brazilian CPC Article 485 carries no res judicata effect on the substantive infringement question. Parties operating in the chemotherapy waste containment space should note that the underlying patent dispute between Grandesc and Bio Brasil remains commercially unsettled even though this case is closed.
Rescission actions can reset decade-old patent judgments in Brazil
This case illustrates that ações rescisórias can effectively nullify final appellate patent rulings years after the original decision. For IP holders and accused infringers alike, the risk of a prior favourable judgment being unwound is a real procedural exposure in the Brazilian system that litigation strategy must account for.
LTDA v BIO — key questions answered
The Court of Justice of São Paulo granted Grandesc’s rescission action, annulling the prior appellate judgment in Appeal No. 1010011-76.2014.8.26.0068 and dismissing the original infringement action without resolution of the merits under CPC Article 485(VI). Bio Brasil was ordered to pay attorney fees of 10% on the case value of R$ 52,501.57.
BRMU1212933U2 is a Brazilian utility model patent registered with INPI, covering an arrangement for a disposable waste box specifically designed for the handling and containment of chemotherapeutic drug derivatives. Utility models in Brazil protect functional innovations in product design and typically carry ten-year protection terms from filing.
A dismissal without resolution of the merits under CPC Article 485(VI) carries no res judicata effect on the substantive infringement question. This means Grandesc could potentially re-file the underlying patent infringement claim in new proceedings, and Bio Brasil has not obtained a finding of non-infringement that would protect it from future suits.
An ação rescisória is a Brazilian civil procedural remedy that allows a party to annul a final judicial decision on specific statutory grounds. In this case, Grandesc used the rescission action to challenge the final appellate ruling made in 2014. The court, sitting as Juízo Rescisório, first annulled that judgment and then issued a fresh ruling — dismissing the original action on procedural grounds rather than the merits.
No. Because the case was resolved on procedural grounds under CPC Article 485(VI) without merits adjudication, the validity of BRMU1212933U2 was never examined by the court. The patent remains in force and potentially enforceable. Companies in the hospital consumables or chemotherapy waste management sector should conduct independent FTO and validity analysis rather than relying on this case outcome as clearance.
PatSnap Eureka searches patents and litigation data to answer instantly.